Yusuke Moritoh

1.5k total citations
30 papers, 939 citations indexed

About

Yusuke Moritoh is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Yusuke Moritoh has authored 30 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Surgery and 16 papers in Molecular Biology. Recurrent topics in Yusuke Moritoh's work include Diabetes Treatment and Management (19 papers), Pancreatic function and diabetes (15 papers) and Peptidase Inhibition and Analysis (10 papers). Yusuke Moritoh is often cited by papers focused on Diabetes Treatment and Management (19 papers), Pancreatic function and diabetes (15 papers) and Peptidase Inhibition and Analysis (10 papers). Yusuke Moritoh collaborates with scholars based in Japan, United Kingdom and Sweden. Yusuke Moritoh's co-authors include Koji Takeuchi, Osamu Kataoka, Masanori Watanabe, Satsuki Miyazaki, Eiji Yamato, Jun‐ichi Miyazaki, Hiroyuki Odaka, Yumiko Yasui, Tomoko Asakawa and Masatoshi Hazama and has published in prestigious journals such as Nature Communications, PLoS ONE and Diabetes.

In The Last Decade

Yusuke Moritoh

28 papers receiving 907 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yusuke Moritoh Japan	18	496	455	420	126	116	30	939
Yu Ihara Japan	13	526 1.1×	524 1.2×	472 1.1×	183 1.5×	135 1.2×	15	1.0k
Yu Togashi Japan	19	371 0.7×	354 0.8×	355 0.8×	155 1.2×	109 0.9×	44	820
Kazumasa Miyawaki Japan	12	775 1.6×	726 1.6×	518 1.2×	259 2.1×	147 1.3×	16	1.3k
Alpana Bhattacharjee Canada	19	309 0.6×	634 1.4×	607 1.4×	200 1.6×	287 2.5×	24	1.4k
Kenji Katsuno Japan	12	545 1.1×	292 0.6×	372 0.9×	44 0.3×	50 0.4×	15	1.0k
Elizabeth Oseid United States	14	549 1.1×	770 1.7×	390 0.9×	316 2.5×	123 1.1×	18	1.0k
Qing Dallas-Yang United States	17	317 0.6×	366 0.8×	684 1.6×	98 0.8×	283 2.4×	19	1.2k
Melissa F. Brereton United Kingdom	12	421 0.8×	652 1.4×	387 0.9×	302 2.4×	126 1.1×	14	1.0k
Janice C. Parker United States	15	262 0.5×	256 0.6×	342 0.8×	52 0.4×	64 0.6×	23	689
Moh Tadayyon Germany	11	487 1.0×	269 0.6×	441 1.1×	40 0.3×	125 1.1×	12	987

Countries citing papers authored by Yusuke Moritoh

Since Specialization

Citations

This map shows the geographic impact of Yusuke Moritoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Moritoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Moritoh more than expected).

Fields of papers citing papers by Yusuke Moritoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Moritoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Moritoh. The network helps show where Yusuke Moritoh may publish in the future.

Co-authorship network of co-authors of Yusuke Moritoh

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Moritoh. A scholar is included among the top collaborators of Yusuke Moritoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Moritoh. Yusuke Moritoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobayashi, Akihiro, Shinichi Abe, Masanori Watanabe, & Yusuke Moritoh. (2022). Liquid chromatography-mass spectrometry measurements of blood diphosphoinositol pentakisphosphate levels. Journal of Chromatography A. 1681. 463450–463450. 3 indexed citations

Moritoh, Yusuke, et al.. (2022). An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria. Kidney International Reports. 8(1). 115–125.

Katayama, Yuko, Y. Kawata, Yusuke Moritoh, & Masanori Watanabe. (2022). Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis. Heliyon. 8(2). e08889–e08889. 14 indexed citations

Moritoh, Yusuke, Shinichi Abe, Akihiro Kobayashi, et al.. (2021). The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals. Nature Communications. 12(1). 4847–4847. 51 indexed citations

Koyama, Ryokichi, et al.. (2021). Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Molecular Pharmacology. 99(4). 286–293. 3 indexed citations

Matsuda, Keisuke, et al.. (2020). The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. Journal of Pharmacology and Experimental Therapeutics. 375(1). 21–27. 21 indexed citations

Sasaki, Masako, Ikuo Miyahisa, Hiroaki Yashiro, et al.. (2019). Discovery and characterization of a small‐molecule enteropeptidase inhibitor, SCO‐792. Pharmacology Research & Perspectives. 7(5). e00517–e00517. 12 indexed citations

Ueno, Hikaru, Ryo Ito, Shinichi Abe, et al.. (2019). SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. Journal of Pharmacology and Experimental Therapeutics. 370(2). 172–181. 31 indexed citations

Ueno, Hikaru, Ryo Ito, Shinichi Abe, et al.. (2019). GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. PLoS ONE. 14(9). e0222653–e0222653. 19 indexed citations

10.

Ramracheya, Reshma, Caroline Chapman, Margarita V. Chibalina, et al.. (2018). GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca ²⁺ channels. Physiological Reports. 6(17). e13852–e13852. 81 indexed citations

11.

Moritoh, Yusuke, Masahiro Oka, Yoshitaka Yasuhara, et al.. (2016). Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice. Scientific Reports. 6(1). 32072–32072. 56 indexed citations

12.

Miyazaki, Satsuki, Yusuke Moritoh, Fumi Tashiro, et al.. (2010). Nuclear Hormone Retinoid X Receptor (RXR) Negatively Regulates the Glucose-Stimulated Insulin Secretion of Pancreatic β-Cells. Diabetes. 59(11). 2854–2861. 37 indexed citations

13.

Miyamoto, Yasufumi, Takashi Yamashita, Tatsuhiko Fujimoto, et al.. (2010). Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorganic & Medicinal Chemistry. 19(1). 172–185. 23 indexed citations

14.

Moritoh, Yusuke, Koji Takeuchi, & Masatoshi Hazama. (2009). Voglibose, an Alpha-glucosidase Inhibitor, to Increase Active Glucagon-like Peptide-1 Levels. 1(4). 188–192. 9 indexed citations

15.

Moritoh, Yusuke, Koji Takeuchi, & Masatoshi Hazama. (2009). Chronic Administration of Voglibose, an α-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice. Journal of Pharmacology and Experimental Therapeutics. 329(2). 669–676. 48 indexed citations

16.

Moritoh, Yusuke, Koji Takeuchi, Takeshi Asakawa, Osamu Kataoka, & Hiroyuki Odaka. (2009). Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in db/db mice. British Journal of Pharmacology. 157(3). 415–426. 42 indexed citations

17.

Moritoh, Yusuke, Koji Takeuchi, & Masaaki Hazama. (2009). Combination treatment with alogliptin and voglibose increases active GLP‐1 circulation, prevents the development of diabetes and preserves pancreatic beta‐cells in prediabetic db/db mice. Diabetes Obesity and Metabolism. 12(3). 224–233. 42 indexed citations

18.

Moritoh, Yusuke, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, & Hiroyuki Odaka. (2008). The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology. 602(2-3). 448–454. 34 indexed citations

19.

Moritoh, Yusuke, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, & Hiroyuki Odaka. (2008). Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. European Journal of Pharmacology. 588(2-3). 325–332. 63 indexed citations

20.

Tanaka, Yasufumi, Yusuke Moritoh, & Nobuhiko Miwa. (2007). Age‐dependent telomere‐shortening is repressed by phosphorylated α‐tocopherol together with cellular longevity and intracellular oxidative‐stress reduction in human brain microvascular endotheliocytes. Journal of Cellular Biochemistry. 102(3). 689–703. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact